• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Healthcare

Versartis Drops on Q3 Numbers, Hires Adviser -- Biotech Movers

The Menlo Park, Calif.-based firm on Thursday reported third-quarter results and said it has hired Cowen to help with evaluating potential transactions.
By ARMIE MARGARET LEE Oct 27, 2017 | 09:35 AM EDT
Stocks quotes in this article: VSAR, SGEN, MNOV

Shares of Versartis Inc. (VSAR) were down 10.9% to $2.05 ahead of the market open on Friday, Oct. 27, after the Menlo Park, Calif.-based firm on Thursday reported third-quarter results and said it has hired Cowen to help with evaluating potential transactions.

The company had a net loss of about  $49.8 million, or $1.40 per share, basic and diluted, compared to a net loss of $27.3 million, or $0.92 per share, basic and diluted, in the same period last year.

The release of the third-quarter numbers came after Versartis in September said its Phase 3 study of somavaratan in pediatric growth hormone deficiency did not achieve its primary endpoint.

"In response to the disappointing outcome of the VELOCITY trial last month, we have been working diligently to understand the results and determine appropriate next steps for the company," said Versartis president and CEO Jay Shepard in a statement.

Shepard said the company is implementing a restructuring to cut costs and preserve cash. At the same time, Versartis has commenced a process to identify opportunities to diversify its pipeline, including potential strategic transactions, he said.

Meanwhile, shares of Seattle Genetics Inc. (SGEN) were up 5.6% to $64.64 after the Bothell, Wash.-based company unveiled third-quarter numbers on Thursday.

The company had revenue of $135.3 million, compared with $106.3 million in the year-ago period. Because of the gain on the Immunomedics warrant, Seattle Genetics reported net income of $50 million, or $0.34 per fully diluted share, compared to a net loss of $31.8 million, or $0.23 per share, for the third quarter of 2016.

As part of its previously terminated license transaction with Immunomedics, Seattle Genetics holds 3 million  Immunomedics shares common stock and a warrant to purchase an additional 8.7 million shares. In September, Immunomedics' resale registration statement covering the shares issuable upon exercise of the warrant was declared effective by the SEC. As a result, the warrant is accounted for as a derivative security and marked-to-market, Seattle Genetics noted.

Among the other stock movers was MediciNova Inc. (MNOV) , up nearly 18% to $7.49. The La Jolla, Calif.-based firm on Thursday morning said its Phase 2b Trial of MN-166 (ibudilast) in progressive multiple sclerosis met both primary endpoints.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from trading individual securities.

TAGS: Investing | U.S. Equity | Healthcare | Stocks

More from Healthcare

A Pullback in TG Therapeutics Looks Like a Buying Opportunity

Bruce Kamich
Jun 8, 2023 8:30 AM EDT

The charts of the biopharmaceutical company are telling a largely bullish story.

Bearish Bets: 3 Stocks You Should Really Consider Shorting This Week

Bob Lang
May 28, 2023 10:30 AM EDT

These recently downgraded names are displaying both quantitative and technical deterioration.

These Small-Cap Biotech Stocks Have the Wind at Their Back

Bret Jensen
May 24, 2023 1:30 PM EDT

After getting a 'win' earlier this week on an acquisition, let's highlight a few similar names in my portfolio.

Why Are CRISPR Therapeutics Charts Saying 'Buy'?

Bruce Kamich
May 15, 2023 1:00 PM EDT

Here's where traders could go long.

Is It Time to Get Back Into CVS Health? Here's a Trade Idea

Stephen Guilfoyle
May 15, 2023 10:30 AM EDT

The fundamentals are not in tip-top shape, and now investors have reduced guidance to deal with.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 07:19 PM EDT CHRIS VERSACE

    AAP Podcast: This Company Is Not Going 'Solo'

    Listen in as I talk with the very diversified Solo...
  • 01:51 PM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Adjusting Your Trading Approach to Shifting Market...
  • 06:54 PM EDT CHRIS VERSACE

    AAP Podcast: A Tongue -- and a Market -- Twister: 'Get a Debt Deal Done'

    Listen in as the Action Alerts PLUS Podcast tackle...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login